Stonebridge Financial Group (Pennsylvania)’s Vertex Pharmaceuticals VRTX Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+433	New	+$192K	0.02%	261
2025 Q2	–	Sell	-415	Closed	-$201K	–	922
2025 Q1	$201K	Buy	415 +5	+1%	+$2.33K	0.02%	220
2024 Q4	$165K	Buy	+410	New	+$190K	0.02%	240

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s VRTX Position: Q2 2026 in Review

Stonebridge Financial Group (Pennsylvania) opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 433 shares worth $215K. The stake represents 0.02% of the portfolio and ranks #261 among its holdings. This is a return to the name: Stonebridge Financial Group (Pennsylvania) previously reported a position in VRTX as recently as Q1 2025.

Stonebridge Financial Group (Pennsylvania) first reported a position in VRTX in Q4 2024 and has held it in 3 quarters since. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Stonebridge Financial Group (Pennsylvania) held 433 shares of Vertex Pharmaceuticals worth $215K as of Q2 2026.
Vertex Pharmaceuticals was a new Stonebridge Financial Group (Pennsylvania) position in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Stonebridge Financial Group (Pennsylvania)'s portfolio in Q2 2026, its #261 holding.
Stonebridge Financial Group (Pennsylvania) first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2026, filed 6 Jul 2026.